// Indépendant · Noté par niveau de preuve · Aucune compensation d'affiliation Cadre Divulgation

Traduction en cours. Le texte original en anglais est affiché ci-dessous ; la terminologie localisée sera revue par un rédacteur clinique de langue maternelle avant publication.

// coaching · clinical report

Noom Clinical Report (2026): Behavior-Change Program with Tracker Attached

Score Breakdown

Cadre d'Évaluation Clinique — 100 points
Critère Poids Sous-note
Preuve et Validation 25% 76/100
Exactitude Clinique 20% 62/100
Performance de Reconnaissance par IA 15% 50/100
Cadre Macronutriments et Objectifs 10% 60/100
Adhésion Comportementale 10% 68/100
Confidentialité et Sécurité 10% 64/100
Coût et Accessibilité 10% 50/100
Total 100% 62/100

Forces / Limites

Forces

  • Psychology curriculum is genuinely thoughtful
  • Color-coded food categorization is beginner-intuitive
  • Optional human coaching as part of the program
  • Multiple published observational studies on weight outcomes

Limites

  • ~$209/year — most expensive in the category by far
  • Trial-conversion pricing is aggressive
  • Calorie tracker functionality is mid-tier at best
  • Cancellation friction is higher than competitors
  • Dropout-attrition handling in published studies has drawn independent criticism

Architecture and Position

Noom delivers a structured behavior-change program (psychology curriculum + coaching + food categorization) rather than a primary calorie tracker. The published evidence base is the strongest of any app on this list — multiple observational studies on weight outcomes from program users. The criticism that recurs in independent reviews concerns attrition handling: published outcomes are conditioned on program completion, which selects for users who were already engaged.

Clinical Evaluation Framework Scoring

CriterionWeightSub-score
Evidence & Validation25%76/100
Clinical Accuracy20%62/100
AI Recognition Performance15%50/100
Macronutrient & Goal Framework10%60/100
Behavioral Adherence10%68/100
Privacy & Security10%64/100
Cost & Accessibility10%50/100

Overall: 62/100. Evidence Grade B.


Last reviewed: 2026-05-22. See our Clinical Evaluation Framework and no-affiliate disclosure.